Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer  with Rare Mutation].

Zhongguo fei ai za zhi = Chinese journal of lung cancer - 20 Jan 2021

Li Teng, Li Junling

Abstract excerpt

Over the past several decades, advances in driven targeted therapy has revolutionized the management of oncogene-driven non-small cell lung cancer (NSCLC). However, there are only a few targeted drugs available for patients with rare mutations, such as BRAF, HER2, MET, RET, etc. In recent years, immune checkpoint inhibitors (ICIs) have demonstrated promising benefit in NSCLC. Till now, efficacy of ICIs for NSCLC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Immune Checkpoint Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins c-met

Share to Receptor, ErbB-2

Source

Open in PubMed Open full text

Identifiers

PMID: 33478186
DOI: 10.3779/j.issn.1009-3419.2020.102.41
PMCID: PMC7849033

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer with Rare Mutation].PMID 33478186Read ↗

Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancerSemantic proximity Read ↗

[Research Progress of Immunotherapy for Non-small Cell Lung Cancer with Drive Gene Mutation].Semantic proximity Read ↗

[Application of Immune Checkpoint Inhibitors in EGFR Mutant Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis.Semantic proximity Read ↗

[Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

[Study Progression on Non-small Cell Lung Cancer with EGFR Mutation Treated by Immune Checkpoint Inhibitors].Semantic proximity Read ↗

[Research Progress in Immune Checkpoint Inhibitors Combination Therapy Applied to Non-small Cell Lung Cancer after EGFR Mutation-targeted Therapy Resistance].Semantic proximity Read ↗

Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations.Semantic proximity Read ↗

[Chinese Expert Consensus on Second-line Treatment for Non-small Cell Lung Cancer with Negative Driver Gene Mutations].Semantic proximity Read ↗

[Current Advance in Targeted Treatment and Immunotherapy for BRAF-mutant Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

[Clinical research and drug review of epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer].Semantic proximity Read ↗

[Current Status and Future Perspectives of Molecular Targeted Therapies for Lung Cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.